{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:13:37Z","timestamp":1788783217269,"version":"build-2803163510"},"reference-count":261,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Bioengineered"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1080\/21655979.2022.2036916","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T12:08:59Z","timestamp":1647346139000},"page":"7709-7745","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population"],"prefix":"10.1080","volume":"13","author":[{"given":"Weixuan","family":"Zhao","sequence":"first","affiliation":[{"name":"the First Hospital of Jilin University, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Meng","sequence":"additional","affiliation":[{"name":"the First Hospital of Jilin University, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"e_1_3_4_2_1","first-page":"211","volume-title":"The","author":"Chen X","year":"2005","unstructured":"Chen X, Jin Y, Tang G. New edition of pharmacology. In: The. 15th ed. Beijing: People\u2019s Medical Publishing House\uff0c; 2005. p. 211.","edition":"15"},{"key":"e_1_3_4_3_1","first-page":"134","article-title":"Pharmacokinetics of oxcarbazepine and its stereoselsctivity","volume":"19","author":"Lu Z","year":"2003","unstructured":"Lu Z, Yu Q. Pharmacokinetics of oxcarbazepine and its stereoselsctivity. Chin J Clin Pharmacol. 2003;19:134.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_4_4_1","first-page":"386","article-title":"Therapeutic drug monitoring of anti-epilepsy drugs","volume":"13","author":"Jiao Z","year":"2004","unstructured":"Jiao Z, Zhong MK, Shi XJ. Therapeutic drug monitoring of anti-epilepsy drugs. China Pharm. 2004;13:386\u2013389.","journal-title":"China Pharm"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)20152-5"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116441"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00279968"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)09721-4"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0361-9230(97)00307-9"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199312000-00001"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050170"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080804"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199310000-00005"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.2001904"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.1955809"},{"issue":"15","key":"e_1_3_4_16_1","first-page":"2774","article-title":"Relationship between hepatic drug-metabolizing enzymes CYP450 and traditional Chinese medicine-induced hepatotoxicity","volume":"41","author":"Hou J","year":"2016","unstructured":"Hou J, Sun E, Song J, et al. Relationship between hepatic drug-metabolizing enzymes CYP450 and traditional Chinese medicine-induced hepatotoxicity. Chin J Chin Mater Med. 2016;41(15):2774\u20132780.","journal-title":"Chin J Chin Mater Med"},{"key":"e_1_3_4_17_1","first-page":"402","article-title":"Progress in cytochrome P450 enzyme in toxicity of traditional Chinese medicines","volume":"26","author":"Liao N","year":"2012","unstructured":"Liao N, Chen W. Progress in cytochrome P450 enzyme in toxicity of traditional Chinese medicines. Chin J Pharmacol Toxicol. 2012;26:402.","journal-title":"Chin J Pharmacol Toxicol"},{"key":"e_1_3_4_18_1","first-page":"241","article-title":"Gene polymorphism and drug metabolism of valproic acid","volume":"16","author":"Bai X","year":"2007","unstructured":"Bai X, Jiang D, Wang Y. Gene polymorphism and drug metabolism of valproic acid. Chin J Drug Depend. 2007;16:241\u2013244.","journal-title":"Chin J Drug Depend"},{"key":"e_1_3_4_19_1","first-page":"99","volume-title":"Pharmacology, the fourth edition","author":"Jiang MX","year":"1996","unstructured":"Jiang MX. Pharmacology, the fourth edition. Beijing: People\u2019s Publishing House; 1996. p. 99."},{"key":"e_1_3_4_20_1","first-page":"422","article-title":"Clinical significance of determination of blood concentration of antiepileptic drugs","volume":"12","author":"Wang XE","year":"1992","unstructured":"Wang XE, Feng Y, Kang Y. Clinical significance of determination of blood concentration of antiepileptic drugs. Chin J Hospital Pharm. 1992;12:422\u2013423.","journal-title":"Chin J Hospital Pharm"},{"key":"e_1_3_4_21_1","first-page":"617","article-title":"Comparison of antiepileptic drugs on embryotoxicity in rats","volume":"33","author":"Wang W","year":"1998","unstructured":"Wang W, Gong S, Li C, et al. Comparison of antiepileptic drugs on embryotoxicity in rats. Chin Pharm J. 1998;33:617\u2013618.","journal-title":"Chin Pharm J"},{"issue":"18","key":"e_1_3_4_22_1","first-page":"3524","article-title":"Interaction between CYP450 enzymes and metabolism of traditional Chinese medicine as well as enzyme activity assay","volume":"40","author":"Lu T","year":"2015","unstructured":"Lu T, Su L, Ji D, et al. Interaction between CYP450 enzymes and metabolism of traditional Chinese medicine as well as enzyme activity assay. Chin J Chin Mater Med. 2015;40(18):3524\u20133529.","journal-title":"Chin J Chin Mater Med"},{"key":"e_1_3_4_23_1","first-page":"1","article-title":"Research progress in genetic polymorphism of CYP450 enzymes related to drug metabolism","volume":"15","author":"Zhao Y","year":"2017","unstructured":"Zhao Y, Xu Z, Liu Y, et al. Research progress in genetic polymorphism of CYP450 enzymes related to drug metabolism. ClinMed J. 2017;15:1\u20136.","journal-title":"ClinMed J"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200011000-00003"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.24"},{"key":"e_1_3_4_26_1","first-page":"1","article-title":"Effects of CYP450 enzymes polymorphisms on plasma valproic acid concentration","volume":"36","author":"Zhang T","year":"2016","unstructured":"Zhang T, Xu S, Liu C, et al. Effects of CYP450 enzymes polymorphisms on plasma valproic acid concentration. Chin J Biochem Pharm. 2016;36:1\u20134.","journal-title":"Chin J Biochem Pharm"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2013.06.012"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)37076-4"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32835ea0b2"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)00359-2"},{"key":"e_1_3_4_31_1","first-page":"133","volume-title":"Innovation driven and transformational development, Proceedings of the Eleventh Annual Conference of Qingdao","author":"Tao W","year":"2013","unstructured":"Tao W. Study on the relationship between CYP2A6 and CYP2B6 gene polymorphisms and sodium valproate plasma concentration. In: Innovation driven and transformational development, Proceedings of the Eleventh Annual Conference of Qingdao, 2013 (Shandong), pp. 133\u2013137."},{"key":"e_1_3_4_32_1","first-page":"745","article-title":"Effect of CYP2A6 genetic polymorphisms on serum concentration of sodium valproate","volume":"11","author":"Sun Y","year":"2006","unstructured":"Sun Y, Tan L, Song J. Effect of CYP2A6 genetic polymorphisms on serum concentration of sodium valproate. Chin J Neurol. 2006;11:745\u2013747.","journal-title":"Chin J Neurol"},{"key":"e_1_3_4_33_1","first-page":"163","article-title":"Determination of pharmacokinetics of sodium valproate in children with epilepsy","volume":"10","author":"Zhong S","year":"1995","unstructured":"Zhong S, Feng S, Jiang Y, et al. Determination of pharmacokinetics of sodium valproate in children with epilepsy. Chin J Appl Clin Pediatr. 1995;10:163\u2013164.","journal-title":"Chin J Appl Clin Pediatr"},{"key":"e_1_3_4_34_1","first-page":"539","article-title":"Interaction between sodium valproate and phenytoin or carbamazepine","volume":"15","author":"Zhang J","year":"1995","unstructured":"Zhang J, Yu L, Qu Z, et al. Interaction between sodium valproate and phenytoin or carbamazepine. Chin J Hospital Pharm. 1995;15:539\u2013540.","journal-title":"Chin J Hospital Pharm"},{"key":"e_1_3_4_35_1","first-page":"197","article-title":"Effects of sodium valproate on clonazepam in pharmacokinetics and its related mechanism","volume":"18","author":"Wang X","year":"1998","unstructured":"Wang X, Wang L. Effects of sodium valproate on clonazepam in pharmacokinetics and its related mechanism. Chin J Hospital Pharm. 1998;18:197\u2013199.","journal-title":"Chin J Hospital Pharm"},{"key":"e_1_3_4_36_1","first-page":"87","volume-title":"Pharmacogenetics","author":"Zhou H","year":"2001","unstructured":"Zhou H. Pharmacogenetics. Vol. 53. Beijing: Science Press; 2001. p. 87\u201399."},{"key":"e_1_3_4_37_1","first-page":"102","volume-title":"Biopharmaceuticals and pharmacokinetics","author":"Liang W","year":"2000","unstructured":"Liang W. Biopharmaceuticals and pharmacokinetics. Beijing: People\u2019s Medical Publishing House; 2000. p. 102."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/ci700262y"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00173169"},{"key":"e_1_3_4_40_1","first-page":"378","article-title":"Association study between valproic acid plasma concentration and CYP286 gene polymorphism","volume":"4","author":"Ou J","year":"2007","unstructured":"Ou J, Tan L, Sun Y. Association study between valproic acid plasma concentration and CYP286 gene polymorphism. Chin J Clin Neurosci. 2007;4:378\u2013381.","journal-title":"Chin J Clin Neurosci"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00004"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfl096"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2003.00148.x"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200002000-00011"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199502000-00004"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03080-y"},{"key":"e_1_3_4_47_1","first-page":"14","article-title":"Study on correlation between CYP2C19 gene polymorphism with serum valproic acid concentration and individualized medication","volume":"39","author":"Zhu Z","year":"2018","unstructured":"Zhu Z, Wang H, Cao X, et al. Study on correlation between CYP2C19 gene polymorphism with serum valproic acid concentration and individualized medication. Int J Lab Med. 2018;39:14\u201316.","journal-title":"Int J Lab Med"},{"key":"e_1_3_4_48_1","first-page":"21","article-title":"Law treatment of acute period of stroke: clinical observation of 98 cases","volume":"32","author":"Cheung NY","year":"2014","unstructured":"Cheung NY. Law treatment of acute period of stroke: clinical observation of 98 cases. Labor Invest. 2014;32:21.","journal-title":"Labor Invest"},{"key":"e_1_3_4_49_1","first-page":"295","article-title":"Effects of CYP2C19 genetic polymorphism on plasma concentration of sodium valproate in epileptic patients","volume":"10","author":"Han R","year":"2015","unstructured":"Han R, Li Y, Wu W. Effects of CYP2C19 genetic polymorphism on plasma concentration of sodium valproate in epileptic patients. Neural Injury Funct Reconstr. 2015;10:295\u2013297.","journal-title":"Neural Injury Funct Reconstr"},{"key":"e_1_3_4_50_1","first-page":"49","article-title":"Distribution of CYP2C19 gene polymorphisms related to valproic acid metabolism in children with epilepsy and individualized treatment study","volume":"18","author":"Feng Y","year":"2015","unstructured":"Feng Y, Zhou J, Liu K, et al. Distribution of CYP2C19 gene polymorphisms related to valproic acid metabolism in children with epilepsy and individualized treatment study. Chin J Pract Nerv Dis. 2015;18:49\u201352.","journal-title":"Chin J Pract Nerv Dis"},{"key":"e_1_3_4_51_1","first-page":"123","article-title":"Study on the relationship between CYP2C9 and CYP2C19 gene polymorphisms and valproic acid concentration in epilepsy patients","volume":"19","author":"Tan X","year":"2011","unstructured":"Tan X, Zhang Y, Wang S, et al. Study on the relationship between CYP2C9 and CYP2C19 gene polymorphisms and valproic acid concentration in epilepsy patients. Pharm Clin Res. 2011;19:123\u2013128.","journal-title":"Pharm Clin Res"},{"issue":"4","key":"e_1_3_4_52_1","first-page":"1066","article-title":"CYP2D6 gene polymorphism and its influence on drug metabolism, China Pharmacy","volume":"26","author":"Han L","year":"2015","unstructured":"Han L, Liu J. CYP2D6 gene polymorphism and its influence on drug metabolism, China Pharmacy. The Journal of Craniofacial Surgery. 2015;26(4):1066\u20131068.","journal-title":"The Journal of Craniofacial Surgery"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/10937400903158342"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920010791196274"},{"key":"e_1_3_4_55_1","first-page":"1066","article-title":"Gene polymorphism of CYP2D6*10 in patients with epilepsy and the effect on serum concentration of sodium valproate","volume":"26","author":"Fang F","year":"2015","unstructured":"Fang F, Fang Z, Zhang D, et al. Gene polymorphism of CYP2D6*10 in patients with epilepsy and the effect on serum concentration of sodium valproate. China Pharm. 2015;26:1066\u20131068.","journal-title":"China Pharm"},{"key":"e_1_3_4_56_1","article-title":"Research progress on the relationship between UGT gene polymorphisms and antiepileptic drug metabolism","volume":"28","author":"Ke J","year":"2021","unstructured":"Ke J, Wang D, Zhu Y. Research progress on the relationship between UGT gene polymorphisms and antiepileptic drug metabolism. Stroke Nervous Dis. 2021;28:226\u2013228+234.","journal-title":"Stroke Nervous Dis"},{"key":"e_1_3_4_57_1","first-page":"112","article-title":"Research progress on the effect of gene polymorphisms on the pharmacokinetics of common antiepileptic drugs","volume":"61","author":"Chen Y","year":"2021","unstructured":"Chen Y, Fan Q. Research progress on the effect of gene polymorphisms on the pharmacokinetics of common antiepileptic drugs. Shandong Med J. 2021;61:112\u2013115.","journal-title":"Shandong Med J"},{"key":"e_1_3_4_58_1","first-page":"216","article-title":"Effects of UGT2B7-C802T and G211T genetic polymorphism on metabolism of valproic acid in epilepsy patients","volume":"35","author":"Sun Y","year":"2015","unstructured":"Sun Y, Zhuo W, Lin H, et al. Effects of UGT2B7-C802T and G211T genetic polymorphism on metabolism of valproic acid in epilepsy patients. Chin Hosp Pharm J. 2015;35:216\u2013219.","journal-title":"Chin Hosp Pharm J"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.021428"},{"key":"e_1_3_4_60_1","first-page":"6","article-title":"Genetic polymorphisms of UGT-glucurono-syltransferase 2B7 in Chinese healthy Han population","volume":"30","author":"He B","year":"2014","unstructured":"He B, Wang W, Zhao X, et al. Genetic polymorphisms of UGT-glucurono-syltransferase 2B7 in Chinese healthy Han population. Chin J Clin Pharmacol. 2014;30:6\u20138.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_4_61_1","first-page":"526","article-title":"Research progress of valproic acid pharmacogenomics","volume":"14","author":"Wen Z","year":"2016","unstructured":"Wen Z, Xiao J, Chen X. Research progress of valproic acid pharmacogenomics. Central South Pharm. 2016;14:526\u2013531.","journal-title":"Central South Pharm"},{"key":"e_1_3_4_62_1","first-page":"586","article-title":"Effect of UGT gene polymorphism on the plasma concentration of valproate acid","volume":"17","author":"Zhang M","year":"2019","unstructured":"Zhang M, Li R, Zhou Y. Effect of UGT gene polymorphism on the plasma concentration of valproate acid. Central South Pharm. 2019;17:586\u2013589.","journal-title":"Central South Pharm"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283544085"},{"key":"e_1_3_4_64_1","first-page":"280","article-title":"Relationship between UGTlA6 A541G and A552C genetic polymorphism and plasma concentration of sodium valproate","volume":"18","author":"Kang W","year":"2016","unstructured":"Kang W, Chen J, Chai D, et al. Relationship between UGTlA6 A541G and A552C genetic polymorphism and plasma concentration of sodium valproate. Chin J Health Care Med. 2016;18:280\u2013283.","journal-title":"Chin J Health Care Med"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.21"},{"key":"e_1_3_4_66_1","first-page":"429","article-title":"Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan","volume":"12","author":"Wang Y","year":"2010","unstructured":"Wang Y, Gao L, Liu Y, et al. Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan. Chin J Contemp Pediatr. 2010;12:429\u2013432.","journal-title":"Chin J Contemp Pediatr"},{"key":"e_1_3_4_67_1","first-page":"802","article-title":"Effect of UGT1A6 genetic polymorphism on serum concentration of valproic acid in Han epileptic patients","volume":"16","author":"Jin L","year":"2013","unstructured":"Jin L, Yang L, Ma M. Effect of UGT1A6 genetic polymorphism on serum concentration of valproic acid in Han epileptic patients. China Pharm. 2013;16:802\u2013804.","journal-title":"China Pharm"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000114771.78957.cb"},{"key":"e_1_3_4_69_1","first-page":"299","article-title":"Study on the correlation between UGT1A6 gene polymorphism and valproic acid concentration in epilepsy patients","volume":"22","author":"Tan X","year":"2014","unstructured":"Tan X, Zhang X, Qiu Z. Study on the correlation between UGT1A6 gene polymorphism and valproic acid concentration in epilepsy patients. Pharm Clin Res. 2014;22:299\u2013301.","journal-title":"Pharm Clin Res"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.07.005"},{"key":"e_1_3_4_71_1","first-page":"1188","article-title":"Progress in the pharmacogenomics of UDP-glucuronosyltransferase","volume":"20","author":"Guo D","year":"2011","unstructured":"Guo D, Pang L, Zhou H. Progress in the pharmacogenomics of UDP-glucuronosyltransferase. Chin J New Drugs. 2011;20:1188\u20131193.","journal-title":"Chin J New Drugs"},{"key":"e_1_3_4_72_1","first-page":"1013","article-title":"Effects of UGTlA6 and UGTlA9 gene polymorphisms on blood concentration of valproic acid in Han epileptic patients","volume":"28","author":"Lin X","year":"2017","unstructured":"Lin X, Zhang Y, Lin P, et al. Effects of UGTlA6 and UGTlA9 gene polymorphisms on blood concentration of valproic acid in Han epileptic patients. China Pharm. 2017;28:1013\u20131017.","journal-title":"China Pharm"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500139"},{"key":"e_1_3_4_74_1","unstructured":"Zou M Study on the correlation between UGT2B7 gene polymorphism and valproic acid blood concentration. MS Thesis Central South University: Changsha 2011."},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0726-4"},{"key":"e_1_3_4_76_1","first-page":"460","article-title":"Distribution of UGT1A9-2152T and UGT2B7-G211T mutations in Chinese Han population","volume":"12","author":"Yi J","year":"2007","unstructured":"Yi J, Xie H, Zhou H. Distribution of UGT1A9-2152T and UGT2B7-G211T mutations in Chinese Han population. Chin J Clin Pharmacol Ther. 2007;12:460\u2013464.","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"e_1_3_4_77_1","first-page":"33","article-title":"Effect of udp-glucuronosyltransferase UGT2B7 genetic polymorphisms on serum valproate concentrations in children with epilepsy","volume":"22","author":"Zhang Q","year":"2016","unstructured":"Zhang Q, Tang H, Lyu X, et al. Effect of udp-glucuronosyltransferase UGT2B7 genetic polymorphisms on serum valproate concentrations in children with epilepsy. J Pediatr Pharm. 2016;22:33\u201336.","journal-title":"J Pediatr Pharm"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1277-7"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2017.09.004"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2013.02.019"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602530701690341"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.04.018"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3028"},{"key":"e_1_3_4_84_1","first-page":"148","article-title":"Effects of quetiapine combined with sodium valproate on agitation and impulsive aggressive behavior in patients with first-episode schizophrenia","volume":"34","author":"Yan J","year":"2015","unstructured":"Yan J, Gao Z, Gong C, et al. Effects of quetiapine combined with sodium valproate on agitation and impulsive aggressive behavior in patients with first-episode schizophrenia. J Southeast Univ (Med Sci Edi). 2015;34:148\u2013150.","journal-title":"J Southeast Univ (Med Sci Edi)"},{"key":"e_1_3_4_85_1","first-page":"1267","article-title":"The effect of multidrug resistance gene haploid on the blood concentration of sodium valproate in Chinese patients with epilepsy","volume":"15","author":"Ding Y","year":"2010","unstructured":"Ding Y, Yang F, Liu J. The effect of multidrug resistance gene haploid on the blood concentration of sodium valproate in Chinese patients with epilepsy. Chin J Clin Pharmacol Ther. 2010;15:1267\u20131272.","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"e_1_3_4_86_1","first-page":"359","article-title":"Research status and progress of inhibiting the function of P-glycoprotein transporter in reversing tumor multidrug resistance","volume":"37","author":"Li J","year":"2018","unstructured":"Li J, Chen B. Research status and progress of inhibiting the function of P-glycoprotein transporter in reversing tumor multidrug resistance. J Southeast Univ (Med Sci Edi). 2018;37:359\u2013363.","journal-title":"J Southeast Univ (Med Sci Edi)"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2015.12.012"},{"key":"e_1_3_4_88_1","first-page":"646","article-title":"Correlation analysis between ABCC2 gene polymorphism with blood concentration of sodium valproate and efficacy in epileptic patients","volume":"47","author":"Liu Y","year":"2019","unstructured":"Liu Y, Zhang X, Wu J. Correlation analysis between ABCC2 gene polymorphism with blood concentration of sodium valproate and efficacy in epileptic patients. Mod Med J. 2019;47:646\u2013651.","journal-title":"Mod Med J"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000002"},{"key":"e_1_3_4_90_1","first-page":"259","article-title":"The value of genetic polymorphisms of mycophenolate mofetil in individualized therapy","volume":"38","author":"Zhang Z","year":"2018","unstructured":"Zhang Z, Xu H. The value of genetic polymorphisms of mycophenolate mofetil in individualized therapy. J Clin Pediatr. 2018;38:259\u2013261.","journal-title":"J Clin Pediatr"},{"key":"e_1_3_4_91_1","first-page":"215","article-title":"Influence of transporter genetic polymorphisms on valproic acid blood concentration and clinical efficacy of epilepsy patients","volume":"32","author":"Chen J","year":"2016","unstructured":"Chen J, Wang X, Zhou L, et al. Influence of transporter genetic polymorphisms on valproic acid blood concentration and clinical efficacy of epilepsy patients. Chin J Clin Pharmacol. 2016;32:215\u2013217.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.1997.0068"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.09.012"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.09.052"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500413"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021986"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318187972a"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001313"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2005.04.010"},{"key":"e_1_3_4_100_1","first-page":"229","volume-title":"Medications for epilepsy","author":"Xi S","year":"2002","unstructured":"Xi S, Teng J. Medications for epilepsy. Henan: Zhengzhou University Press; 2002. p. 229."},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200023337054"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200007000-00001"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.103"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2015.09.001"},{"key":"e_1_3_4_105_1","unstructured":"Yun W Genetic analysis of individual differences in the metabolism of antiepileptic drug carbamazepine. MS Thesis Jilin University: Changchun 2015."},{"key":"e_1_3_4_106_1","unstructured":"Wang J Correlation between CYP3A5 subfamily gene polymorphisms and carbamazepine concentration and efficacy in Chinese Han patients with epilepsy. PhD Dissertation Fudan University: Shanghai 2012."},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/86882"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.0618"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2007.00791.x"},{"key":"e_1_3_4_110_1","unstructured":"Ren J Study on the correlation between CYP3A5 gene polymorphism and carbamazepine plasma concentration. MS Thesis Jilin University: Changchun 2010."},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01057.x"},{"key":"e_1_3_4_112_1","first-page":"3433","article-title":"Effects of CYP3A5 gene polymorphism on steady state serum concentrations and therapeutic efficacy of carbamazepine in chinese han epileptic patients","volume":"25","author":"Liu J","year":"2014","unstructured":"Liu J, Li Y, Zhang G, et al. Effects of CYP3A5 gene polymorphism on steady state serum concentrations and therapeutic efficacy of carbamazepine in chinese han epileptic patients. China Pharm. 2014;25:3433\u20133435.","journal-title":"China Pharm"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.02.009"},{"key":"e_1_3_4_114_1","unstructured":"Zhang W Study on the relationship between UGT2B7*2 gene polymorphisms and blood levels of carbamazepine and valproic acid in patients with epilepsy. PhD Dissertation BaoTou Medical College Inner Mongolia University of Science and Technology: Baotou 2015."},{"key":"e_1_3_4_115_1","unstructured":"Qu J Effects of ABCB1 ABCC2 CYP3A5 and UGT2B7 gene polymorphisms on the efficacy of antiepileptic drugs. PhD Dissertation Central South University: Changsha 2012."},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2006.01.002"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.10.048"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.32"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0878-1"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.7.4.551"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.02.015"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03140.x"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.12301.x"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328338073a"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02397.x"},{"key":"e_1_3_4_126_1","first-page":"6","article-title":"Research progress of individualized medication of phenytoin sodium guided by gene","volume":"30","author":"Zhang L","year":"2018","unstructured":"Zhang L. Research progress of individualized medication of phenytoin sodium guided by gene. Strait Pharm J. 2018;30:6\u20139.","journal-title":"Strait Pharm J"},{"key":"e_1_3_4_127_1","first-page":"43","article-title":"Potentially unsafe herb-drug interactions between a commercial product of noni juice and phenytoin-a case report","volume":"24","author":"Kang Y","year":"2015","unstructured":"Kang Y, Chen M, Lai S. Potentially unsafe herb-drug interactions between a commercial product of noni juice and phenytoin-a case report. Acta Neurol. 2015;24:43\u201346.","journal-title":"Acta Neurol"},{"issue":"2","key":"e_1_3_4_128_1","first-page":"213","article-title":"a case of phenytoin intoxication caused by interaction between phenytoin and capecitabine","volume":"67","author":"Taguchi Y","year":"2015","unstructured":"Taguchi Y, Takashima S, Tanaka K. a case of phenytoin intoxication caused by interaction between phenytoin and capecitabine. Brain Nerve. 2015;67(2):213\u2013217.","journal-title":"Brain Nerve"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90650-U"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1992.tb11329.x"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)00641-J"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200106000-00002"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.28"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00721.x"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.690"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9781-2"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181fa97cc"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009343006"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.63.10_suppl_4.S3"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00076-5"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.185"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.22"},{"key":"e_1_3_4_143_1","article-title":"Influence of CYP2C19 and CYP2C9 gene polymorphisms on phenytoin concentrations in Chinese Han epileptic patients","volume":"27","author":"Ren X","year":"2011","unstructured":"Ren X, Wang X, Xu X, et al. Influence of CYP2C19 and CYP2C9 gene polymorphisms on phenytoin concentrations in Chinese Han epileptic patients. Chin J Clin Pharmacol. 2011;27:249\u2013251+264.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.4238\/vol9-3gmr938"},{"key":"e_1_3_4_145_1","first-page":"98","article-title":"Clinical effects of individualized administration of PHT in epileptic children guided by TDM combined with CYP2C19 genotype","volume":"16","author":"Zhou J","year":"2019","unstructured":"Zhou J, Dong F, Wu G, et al. Clinical effects of individualized administration of PHT in epileptic children guided by TDM combined with CYP2C19 genotype. Chin J Pract Med. 2019;16:98\u2013101.","journal-title":"Chin J Pract Med"},{"key":"e_1_3_4_146_1","first-page":"922","article-title":"Association of plasma sodium phenytoin concentration with CYP2C19 gene polymorphism","volume":"10","author":"Qi X","year":"2004","unstructured":"Qi X, Huang Y, Wang Y, et al. Association of plasma sodium phenytoin concentration with CYP2C19 gene polymorphism. Chin J New Drugs. 2004;10:922\u2013925.","journal-title":"Chin J New Drugs"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00477.x"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.1.29"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000141021.42763.F6"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.6.4.411"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.255"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02059.x"},{"key":"e_1_3_4_153_1","first-page":"2482","article-title":"Association study of ABCB1 genetic polymorphism and the effect of epilepsy with phenytoin treatment","volume":"9","author":"Jiang D","year":"2015","unstructured":"Jiang D, Huang C, Wang B, et al. Association study of ABCB1 genetic polymorphism and the effect of epilepsy with phenytoin treatment. Chin J Clinicians. 2015;9:2482\u20132486.","journal-title":"Chin J Clinicians"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.10.004"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-017-0808-5"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12263"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2011.03.028"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02588.x"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.894023"},{"key":"e_1_3_4_160_1","first-page":"17","article-title":"Clinical pharmacokinetics of gabapentin","volume":"44","author":"McLean MJ","year":"1994","unstructured":"McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44:17\u201322.","journal-title":"Neurology"},{"key":"e_1_3_4_161_1","first-page":"336","article-title":"Evaluation of the absorption, excretion, pharmacokinefics and metabolism of anticonvulsant topiramate in healthy men","volume":"11","author":"Wu W","year":"1994","unstructured":"Wu W, Heebner JB, Streeter AJ. Evaluation of the absorption, excretion, pharmacokinefics and metabolism of anticonvulsant topiramate in healthy men. Pharm Res. 1994;11:336.","journal-title":"Pharm Res"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.1684\/j.1950-6945.2003.tb00026.x"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003400245"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-4388(97)80085-2"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25561"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.09.065"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70078-0"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03085-2"},{"issue":"16","key":"e_1_3_4_169_1","first-page":"4187","article-title":"Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11","volume":"51","author":"Kawato Y","year":"1991","unstructured":"Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187\u20134191.","journal-title":"Cancer Res"},{"issue":"24","key":"e_1_3_4_170_1","first-page":"6921","article-title":"Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis","volume":"60","author":"Ando Y","year":"2000","unstructured":"Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60(24):6921\u20136926.","journal-title":"Cancer Res"},{"key":"e_1_3_4_171_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033988"},{"key":"e_1_3_4_172_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20131"},{"key":"e_1_3_4_173_1","first-page":"180","article-title":"The relationship between the distribution characteristics of UGT1A4 gene and its polymorphisms and the blood concentration of lamotrigine in patients with epilepsy in Han nationality in northern China","volume":"48","author":"Yang L","year":"2015","unstructured":"Yang L, Lin W, Zhang J, et al. The relationship between the distribution characteristics of UGT1A4 gene and its polymorphisms and the blood concentration of lamotrigine in patients with epilepsy in Han nationality in northern China. Chinese J Neurol. 2015;48:180\u2013184.","journal-title":"Chinese J Neurol"},{"key":"e_1_3_4_174_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21362"},{"key":"e_1_3_4_175_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022731"},{"key":"e_1_3_4_176_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200110000-00008"},{"key":"e_1_3_4_177_1","first-page":"2737","article-title":"Quantitative estimation of blood concentration of lamotrigine in Chinese Han pediatric patients with epilepsy based on UGT1A4 142T>G polymorphism and blood concentration of valproic acid","volume":"28","author":"He Y","year":"2017","unstructured":"He Y, He F, Mo X, et al. Quantitative estimation of blood concentration of lamotrigine in Chinese Han pediatric patients with epilepsy based on UGT1A4 142T>G polymorphism and blood concentration of valproic acid. China Pharm. 2017;28:2737\u20132742.","journal-title":"China Pharm"},{"key":"e_1_3_4_178_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1925-9"},{"key":"e_1_3_4_179_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1449-5"},{"key":"e_1_3_4_180_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181ceecc6"},{"key":"e_1_3_4_181_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2008-2"},{"key":"e_1_3_4_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2015.05.002"},{"key":"e_1_3_4_183_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12984"},{"key":"e_1_3_4_184_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000271"},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990457"},{"key":"e_1_3_4_186_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9254-z"},{"key":"e_1_3_4_187_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00733"},{"key":"e_1_3_4_188_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.317"},{"key":"e_1_3_4_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.12.032"},{"key":"e_1_3_4_190_1","unstructured":"Lu R Study on the correlation between drug gene polymorphism and lamotrigine plasma concentration in patients with epilepsy. PhD Dissertation Zhejiang University: Hangzhou 2016."},{"issue":"8","key":"e_1_3_4_191_1","first-page":"9533","article-title":"Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai","volume":"8","author":"Zhou Y","year":"2015","unstructured":"Zhou Y, Ye W, Wang Y, et al. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. Int J Clin Exp Pathol. 2015;8(8):9533\u20139542.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_4_192_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2005.04.039"},{"key":"e_1_3_4_193_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.01.015"},{"key":"e_1_3_4_194_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f974dc"},{"key":"e_1_3_4_195_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9752-7"},{"key":"e_1_3_4_196_1","unstructured":"He Y Pharmacogenomics-based research on individualized medication of lamotrigine in the treatment of epilepsy patients in southern China. PhD Dissertation Southern Medical University: Guangzhou 2017."},{"key":"e_1_3_4_197_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31817fd4d4"},{"key":"e_1_3_4_198_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00561.2006"},{"key":"e_1_3_4_199_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31826517c6"},{"key":"e_1_3_4_200_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1606-5"},{"key":"e_1_3_4_201_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2013.07.016"},{"key":"e_1_3_4_202_1","unstructured":"Huang W Population pharmacokinetics study of lamotrigine in the treatment of epilepsy based on genetic polymorphisms of metabolic enzymes transporters and receptors. PhD Dissertation Guangzhou Medical University: Guangzhou 2017."},{"key":"e_1_3_4_203_1","first-page":"2069","article-title":"Influences of sodium channel gene and transporter gene polymorphisms on lamotrigine concentration","volume":"32","author":"Chen Y","year":"2016","unstructured":"Chen Y, Xu S, Qiu F, et al. Influences of sodium channel gene and transporter gene polymorphisms on lamotrigine concentration. Chin J Clin Pharmacol. 2016;32:2069\u20132072.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_4_204_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000210517.03902.6e"},{"key":"e_1_3_4_205_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.12.152S.35254"},{"key":"e_1_3_4_206_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2015.03.019"},{"key":"e_1_3_4_207_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.07.004"},{"key":"e_1_3_4_208_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1083424"},{"key":"e_1_3_4_209_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.186"},{"key":"e_1_3_4_210_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014814924965"},{"key":"e_1_3_4_211_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115020-00005"},{"key":"e_1_3_4_212_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.11.1257"},{"key":"e_1_3_4_213_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.067660"},{"key":"e_1_3_4_214_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.167361"},{"key":"e_1_3_4_215_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00924.x"},{"key":"e_1_3_4_216_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1118774"},{"key":"e_1_3_4_217_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.33"},{"key":"e_1_3_4_218_1","unstructured":"Wang P Study on the correlation between CYP3A4\/3A5 ABCB1 gene polymorphism and the plasma concentration of carbamazepine oxcarbazepine and its main metabolites. PhD Dissertation Central South University: Changsha 2014."},{"key":"e_1_3_4_219_1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2004.245"},{"key":"e_1_3_4_220_1","first-page":"595","article-title":"Relationship between cytochromes P450 2C19* 2 genotype and the concentration of the active oxcarbazepine metabolite in pediatric patients with epilepsy","volume":"33","author":"Zhou X","year":"2017","unstructured":"Zhou X, Ma L, Xiang Q, et al. Relationship between cytochromes P450 2C19* 2 genotype and the concentration of the active oxcarbazepine metabolite in pediatric patients with epilepsy. Chin J Clin Pharmacol. 2017;33:595\u2013598.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_4_221_1","first-page":"2017","article-title":"Genetic polymorphism analysis of cytochrome CYP3A4, CYP2C9, CYP2C19, CYP2D6 in Chinese Han and Mongolian population","volume":"47","author":"Xia D","year":"2012","unstructured":"Xia D, Zuo J, Zhao D, et al. Genetic polymorphism analysis of cytochrome CYP3A4, CYP2C9, CYP2C19, CYP2D6 in Chinese Han and Mongolian population. China Pharm. 2012;47:2017\u20132022.","journal-title":"China Pharm"},{"key":"e_1_3_4_222_1","volume-title":"Preliminary theoretical analysis of pharmacokinetics and metabolic differences between oxcarbazepine and carbamazepine","author":"Mu D","year":"2006","unstructured":"Mu D. Preliminary theoretical analysis of pharmacokinetics and metabolic differences between oxcarbazepine and carbamazepine. Tianjin: Tianjin University; 2006."},{"key":"e_1_3_4_223_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2395-z"},{"key":"e_1_3_4_224_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.009787"},{"key":"e_1_3_4_225_1","unstructured":"Zhang W Analysis of the efficacy and influencing factors of oxcarbazepine in children with epilepsy. PhD Dissertation Fujian Medical University: Fuzhou 2019."},{"key":"e_1_3_4_226_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2157-3"},{"key":"e_1_3_4_227_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1409-0"},{"key":"e_1_3_4_228_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00437"},{"key":"e_1_3_4_229_1","first-page":"1796","article-title":"Research progress of relationship between the UGT2B7 genetic polymorphisms and the risk of cancers","volume":"31","author":"He N","year":"2015","unstructured":"He N, Zhao X, Zhang W. Research progress of relationship between the UGT2B7 genetic polymorphisms and the risk of cancers. Chin J Clin Pharmacol. 2015;31:1796\u20131798.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_4_230_1","unstructured":"Ma C Effect of gene polymorphism on the pharmacokinetics and pharmacodynamics of carbamazepine and its derivative oxcarbazepine. PhD Dissertation Fudan University: Shanghai 2013."},{"key":"e_1_3_4_231_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100324"},{"key":"e_1_3_4_232_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2017.07.015"},{"key":"e_1_3_4_233_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2016-0014"},{"key":"e_1_3_4_234_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200011000-00002"},{"key":"e_1_3_4_235_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01302.x"},{"key":"e_1_3_4_236_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.11.011"},{"key":"e_1_3_4_237_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.2.3"},{"key":"e_1_3_4_238_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12863-016-0434-x"},{"key":"e_1_3_4_239_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0801-x"},{"key":"e_1_3_4_240_1","unstructured":"Yue L The distribution of ABCB1 gene polymorphism in patients with epilepsy and its correlation with the efficacy of antiepileptic drugs. PhD Dissertation Fudan University: Shanghai 2010."},{"key":"e_1_3_4_241_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2005.04.006"},{"key":"e_1_3_4_242_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.569"},{"key":"e_1_3_4_243_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.43.100901.140233"},{"key":"e_1_3_4_244_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00064-9"},{"key":"e_1_3_4_245_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200111160-00037"},{"key":"e_1_3_4_246_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945011795378487"},{"key":"e_1_3_4_247_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.141"},{"key":"e_1_3_4_248_1","first-page":"424","article-title":"How does P-glycoprotein recognize its substrates?","volume":"45","author":"Ueda K","year":"1997","unstructured":"Ueda K, Taguchi Y, Morishima M. How does P-glycoprotein recognize its substrates? Semin Cancer Biol. 1997;45:424\u2013429.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"e_1_3_4_249_1","first-page":"449","article-title":"Comment letters","volume":"47","author":"Silvio B","year":"2006","unstructured":"Silvio B, Sanja H, Poljakovic Z. Comment letters. Epilepsia. 2006;47(2):449\u2013452.","journal-title":"Epilepsia"},{"key":"e_1_3_4_250_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00414.x"},{"key":"e_1_3_4_251_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh437"},{"key":"e_1_3_4_252_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-14-05833.2002"},{"key":"e_1_3_4_253_1","first-page":"42","article-title":"Antiepileptic drug-induced overexpression of P-glycoprotein-multidrug resistance gene in astrocytes in vitro","volume":"34","author":"Lv Y","year":"2001","unstructured":"Lv Y, Yan Y, Wang X, et al. Antiepileptic drug-induced overexpression of P-glycoprotein-multidrug resistance gene in astrocytes in vitro. Chin J Neurol. 2001;34:42\u201344.","journal-title":"Chin J Neurol"},{"key":"e_1_3_4_254_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.156702.x"},{"key":"e_1_3_4_255_1","first-page":"4","article-title":"Intractable epilepsy","volume":"31","author":"Wu X","year":"1998","unstructured":"Wu X, Shen D. Intractable epilepsy. Chin J Neurol. 1998;31:4\u20136.","journal-title":"Chin J Neurol"},{"key":"e_1_3_4_256_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051053"},{"key":"e_1_3_4_257_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f85e36"},{"key":"e_1_3_4_258_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3473"},{"key":"e_1_3_4_259_1","unstructured":"Zheng X Study on the relationship between the drug resistance of refractory epilepsy and the pharmacological mechanism of levetiracetam and the polymorphism of MDR1 C3435T. PhD Dissertation Tianjin Medical University: Tianjin 2009."},{"key":"e_1_3_4_260_1","unstructured":"Gao Q Study on population pharmacokinetics of levetiracetam and polymorphism of MDR1 C3435T in patients with epilepsy. PhD Dissertation Fujian Medical University: Fuzhou 2014."},{"key":"e_1_3_4_261_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000137051.33486.C7"},{"key":"e_1_3_4_262_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.04.013"}],"container-title":["Bioengineered"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21655979.2022.2036916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:17:16Z","timestamp":1759159036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21655979.2022.2036916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":261,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1080\/21655979.2022.2036916"],"URL":"https:\/\/doi.org\/10.1080\/21655979.2022.2036916","relation":{},"ISSN":["2165-5979","2165-5987"],"issn-type":[{"value":"2165-5979","type":"print"},{"value":"2165-5987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kbie20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kbie20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}